Shao Yu-Yun, Ho Ching-Liang, Chang Cheng-Shyong, Chang Chia-Lun, Lee Jen-Kuang, Lin Hung-Ju, Hsiao Hui-Hua, Chao Ta-Chung, Lin Ching-Yeh, Liaw Chuang-Chi
Department of Oncology, National Taiwan University Hospital.
Graduate Institute of Oncology, National Taiwan University College of Medicine.
Acta Cardiol Sin. 2023 Mar;39(2):242-253. doi: 10.6515/ACS.202303_39(2).20220719A.
Cancer-associated thrombosis (CAT) is a common complication of malignancies. Patients with CAT are at risk of venous thromboembolism recurrence, but also at risk of bleeding while anticoagulated. Taiwanese patients are perceived to have a lower incidence of CAT, likely leading to false reassurance for Taiwanese patients with cancer. Because of this, oncologists and cardiologists from multiple medical institutions in Taiwan have set forth to provide clinical consensus guidelines on the management of CAT, based on local clinical practices and guided by predominant international clinical practice guidelines. This paper aims to describe the current disease burden of cancer-associated venous thromboembolism in Taiwanese cancer patients, and discusses the unmet needs and gaps in the management of this medical complication. It also outlines diagnostic and management strategies relevant to the different treatment options available, such as non-vitamin K antagonist oral anticoagulants.
癌症相关血栓形成（CAT）是恶性肿瘤的常见并发症。患有CAT的患者有静脉血栓栓塞复发的风险，同时在接受抗凝治疗时也有出血风险。台湾患者被认为CAT发病率较低，这可能会让台湾癌症患者产生错误的安心感。因此，台湾多家医疗机构的肿瘤学家和心脏病学家已着手根据当地临床实践并在主要国际临床实践指南的指导下，提供关于CAT管理的临床共识指南。本文旨在描述台湾癌症患者中癌症相关静脉血栓栓塞的当前疾病负担，并讨论该医学并发症管理方面未满足的需求和差距。它还概述了与可用的不同治疗选择（如非维生素K拮抗剂口服抗凝剂）相关的诊断和管理策略。
